Cleo DiagnosticsASX:COV +5.32%17 Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 327 Medical Devices & Instruments companies, Cleo Diagnostics ranks worse than 305810.09% on this metric.
As of today (2026-06-24), the Trailing Annual Dividend Yield of Cleo Diagnostics is 0.00%.
The historical rank and industry rank for Cleo Diagnostics's Dividend Yield % or its related term are showing as below:
ASX:COV's Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.98 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Cleo Diagnostics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:COV vs ABT, SYK, MDT: Dividend Yield % Comparison
For the Medical Devices subindustry, Cleo Diagnostics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleo Diagnostics Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cleo Diagnostics's Dividend Yield % falls into.
Cleo Diagnostics (ASX:COV) has a Dividend Yield % of 0.00% as of Jun. 24, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Cleo Diagnostics and its competitors. According to the industry distribution chart, Cleo Diagnostics ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is Cleo Diagnostics' Dividend Yield % too high?
Cleo Diagnostics' current Dividend Yield % is 0.00%. Based on the distribution chart, Cleo Diagnostics ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Dividend Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cleo Diagnostics ranks #999999 out of 327 companies for Dividend Yield %. This places Cleo Diagnostics in the lower half of its industry. The industry median Dividend Yield % is 1.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Medical Devices & Instruments company?
The median Dividend Yield % among Medical Devices & Instruments companies is 1.98, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Cleo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Dividend Yield % is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleo Diagnostics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score
Get the complete analysis for ASX:COV
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:COV has been successfully added to your 